Minerva Surgical (NASDAQ:UTRS – Get Rating) had its target price lowered by Piper Sandler from $12.00 to $6.00 in a research report issued on Thursday, The Fly reports. Piper Sandler’s price target points to a potential upside of 201.51% from the stock’s current price.
Separately, Zacks Investment Research cut shares of Minerva Surgical from a “buy” rating to a “hold” rating in a research report on Saturday, March 12th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $10.50.
NASDAQ UTRS opened at $1.99 on Thursday. Minerva Surgical has a 52 week low of $1.75 and a 52 week high of $10.37. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.60 and a current ratio of 3.29. The company has a 50-day moving average price of $4.13 and a two-hundred day moving average price of $5.46.
Several large investors have recently modified their holdings of the company. Virtu Financial LLC acquired a new stake in shares of Minerva Surgical in the 4th quarter worth approximately $54,000. Renaissance Technologies LLC acquired a new stake in shares of Minerva Surgical in the 4th quarter worth approximately $78,000. BlackRock Inc. acquired a new stake in shares of Minerva Surgical in the 4th quarter worth approximately $88,000. Millennium Management LLC acquired a new stake in Minerva Surgical during the fourth quarter valued at approximately $134,000. Finally, Ghisallo Capital Management LLC acquired a new stake in Minerva Surgical during the fourth quarter valued at approximately $386,000. 69.55% of the stock is owned by institutional investors.
About Minerva Surgical (Get Rating)
Minerva Surgical, Inc, a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps.
- Get a free copy of the StockNews.com research report on Minerva Surgical (UTRS)
- Corning Stock is a Technology Value Play
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
- Wolverine Worldwide Is Ready To Rebound
- Wendy’s Growth Story Has Come To An End
- Can Six Flags(SIX) or Cedar Fair (FUN) Give Investors a Thrill Later This Year?
Receive News & Ratings for Minerva Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Surgical and related companies with MarketBeat.com's FREE daily email newsletter.